Furukawa O, Kume E, Sugamoto S, Kawauchi S, Takeuchi K
Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto, Japan.
Digestion. 2000;62(2-3):116-25. doi: 10.1159/000007804.
The antiulcer drug ecabet 2Na (12-sulfodehydroabietic acid disodium salt) exhibits a gastroprotective activity, mainly through a local action, involving endogenous prostaglandins (PGs) and nitric oxide (NO). In the present study, we examined the effect of ecabet on the epithelial restitution of the bullfrog gastric mucosa in vitro following injury by hypertonic NaCl.
Bullfrog fundic mucosa was mounted in an Ussing chamber. The tissue injury was induced by exposure of the mucosa to 1.25 M NaCl for 5 min, and transmucosal potential difference (PD) and electrical resistance (R) were measured during a 4-hour test period. Ecabet (3-30 mg/ml) was added to the luminal solution for 10 min before or after NaCl, while 16,16-dimethyl PGE(2) (dmPGE(2): 1x 10(-6) M) or NOR-3 (a NO donor: 1 x 10(-4) M) was added to the nutrient solution 10 min before NaCl.
Mucosal application of 1.25 M NaCl caused an immediate reduction of PD and R, followed by a gradual normalization, reaching about 70% of the pre-exposure levels within 4 h. Ecabet, added before NaCl, significantly expedited the recovery of PD and R in a concentration-dependent manner; this effect was mimicked by posttreatment with ecabet and significantly mitigated by prior addition of indomethacin (1 x 10(-5) M) or N(G)-nitro-L-arginine methyl ester (L-NAME: 1 x 10(-3) M). The epithelial restitution was also significantly promoted by serosal application of either dmPGE(2) or NOR-3. The mucosal exposure to ecabet significantly increased the luminal release of PGE(2) and NO metabolites, the effects being attenuated by indomethacin and L-NAME, respectively. The mucous secretion was increased by ecabet as well as dmPGE(2) and NOR-3, and the effect of ecabet was significantly suppressed by both indomethacin and L-NAME. The inhibitory effects of L-NAME on the ecabet action were all significantly antagonized by concurrent addition of L-arginine.
These results suggest that ecabet significantly expedited the restitution following gastric surface cell injury, and this action is mediated by endogenous NO as well as PGs and may be functionally associated with an increase of mucous secretion.
抗溃疡药物依卡倍特二钠(12-磺基脱氢枞酸二钠盐)具有胃保护活性,主要通过局部作用发挥,涉及内源性前列腺素(PGs)和一氧化氮(NO)。在本研究中,我们检测了依卡倍特对牛蛙胃黏膜在高渗氯化钠损伤后体外上皮修复的影响。
将牛蛙胃底黏膜安装在尤斯灌流小室中。通过将黏膜暴露于1.25 M氯化钠中5分钟诱导组织损伤,并在4小时的测试期内测量跨黏膜电位差(PD)和电阻(R)。在氯化钠处理前或后10分钟,将依卡倍特(3 - 30 mg/ml)添加到腔液中,而在氯化钠处理前10分钟,将16,16-二甲基前列腺素E2(dmPGE2:1×10−6 M)或NOR-3(一种NO供体:1×10−4 M)添加到营养液中。
黏膜应用1.25 M氯化钠导致PD和R立即降低,随后逐渐恢复正常,在4小时内达到暴露前水平的约70%。在氯化钠处理前添加依卡倍特以浓度依赖的方式显著加速了PD和R的恢复;依卡倍特处理后也出现这种效果,而预先添加吲哚美辛(1×10−5 M)或N(G)-硝基-L-精氨酸甲酯(L-NAME:1×10−3 M)可显著减轻这种效果。通过浆膜应用dmPGE2或NOR-3也可显著促进上皮修复。黏膜暴露于依卡倍特显著增加了PGE2和NO代谢产物的腔内释放,吲哚美辛和L-NAME分别减弱了这些作用。依卡倍特以及dmPGE2和NOR-3均可增加黏液分泌,吲哚美辛和L-NAME均显著抑制了依卡倍特的作用。同时添加L-精氨酸可显著拮抗L-NAME对依卡倍特作用的抑制效果。
这些结果表明依卡倍特显著加速了胃表面细胞损伤后的修复,且该作用由内源性NO以及PGs介导,可能在功能上与黏液分泌增加有关。